Loading stock data…
FMS
$22.35+0.56 (+2.57%)
After Hours$22.35+0.00 (+0.00%)· Last close Jun 9
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fresenius Medical Care AG in the Healthcare sector is trading at $22.35. Wall Street consensus targets $26.51 (7 analysts), implying a +18.6% move over the next 12 months. The stock is currently 23% below its 52-week high of $29.07, remaining 2.1% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +18.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$22.35
Potential Downside
0%
Whystock Fair Value$22.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Hold
Mean target$26.51+18.6%
Range$17.85 – $37.75
Fundamentals
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a ne...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.13%
Volume
Today's trading volume
559,738
Recent News
FMS and Home Dialysis: How 5008X Could Reset Demand
FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.
FMS Launches kinexus Digital Platform for Home Dialysis Care
Fresenius Medical Care launches kinexus, a home dialysis platform integrating remote monitoring, prescription management and supply ordering for PD and HHD.
DaVita Expands Comprehensive Kidney Care Through Dialysis Services
DVA expands kidney-care reach with integrated CKD/ESKD coordination and 2026 AI scheduling tech to boost dialysis efficiency.
DaVita Gains 21.4% in Three Months: How Should You Play the Stock?
DVA raises guidance on stronger dialysis volumes and reimbursement gains, but rising patient-care and technology costs could squeeze margins.
Fresenius (FMS) Q1 2026 Earnings Transcript
Helen Giza: Thank you, Dominik. Thank you for your continued interest in Fresenius Medical Care. On 30th of April, we successfully completed our initial share buyback program of EUR 1 billion in a significantly accelerated way.